Abstract
We investigated alterations in plasma metabolites associated with the age-related increase in circulating concentration of low-density lipoprotein (LDL)-cholesterol. The study included 602 healthy, nondiabetic subjects (aged 30–65 years). Among 393 individuals with LDL-cholesterol within the normal limit at baseline, 56 (14.2 %) developed high fasting LDL-cholesterol levels after 3 years. The 337 subjects that retained normal LDL-cholesterol were matched for age, gender, BMI, and fasting LDL-cholesterol to form the control group (n = 78). At the 3-year follow-up, the high-LDL group showed greater increases in serum total-cholesterol and LDL-cholesterol, plasma oxidized LDL, lipoprotein-associated phospholipase A2 activity, and urinary 8-epi-prostaglandin F2α than the control group after adjusting for baseline levels. The high-LDL group also showed significant decreases in sphingomyelin (SM) (d18:0/16:1) and phosphatidylcholine (PC) (18:0/20:4), which were associated with an increases on LDL-cholesterol, and significant increases in palmitic amide and lactosylceramide. Mean changes in the levels of SM (d18:0/16:1), C17 sphinganine, PC (18:0/20:4), and eight lysoPCs containing C16:1, C16:0, C17:0, C18:1, C18:0, C20:4, C20:3, and C22:6 were statistically different between control and high-LDL groups. Overall, the change in ox-LDL positively correlated with changes in LDL-cholesterol, Lp-PLA2 activity, palmitic amide, oleamide, lysoPCs, and C17 sphinganine, and negatively correlated with changes in SM (d18:0/16:1) (r = −0.501, P < 0.001). An age-related increase in LDL-cholesterol is associated with enhanced oxidative stress and disturbed sphingolipid metabolism.
| Original language | English |
|---|---|
| Pages (from-to) | 40-49 |
| Number of pages | 10 |
| Journal | Metabolomics |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Biochemistry
- Clinical Biochemistry
Cite this
}
Age-related increase in LDL-cholesterol is associated with enhanced oxidative stress and disturbed sphingolipid metabolism. / Jung, Saem; Kim, Minjoo; Ryu, Hyo Jeong; Chae, Jey Sook; Lee, Sang Hyun; Lee, Jong Ho.
In: Metabolomics, Vol. 11, No. 1, 01.01.2014, p. 40-49.Research output: Contribution to journal › Article
TY - JOUR
T1 - Age-related increase in LDL-cholesterol is associated with enhanced oxidative stress and disturbed sphingolipid metabolism
AU - Jung, Saem
AU - Kim, Minjoo
AU - Ryu, Hyo Jeong
AU - Chae, Jey Sook
AU - Lee, Sang Hyun
AU - Lee, Jong Ho
PY - 2014/1/1
Y1 - 2014/1/1
N2 - We investigated alterations in plasma metabolites associated with the age-related increase in circulating concentration of low-density lipoprotein (LDL)-cholesterol. The study included 602 healthy, nondiabetic subjects (aged 30–65 years). Among 393 individuals with LDL-cholesterol within the normal limit at baseline, 56 (14.2 %) developed high fasting LDL-cholesterol levels after 3 years. The 337 subjects that retained normal LDL-cholesterol were matched for age, gender, BMI, and fasting LDL-cholesterol to form the control group (n = 78). At the 3-year follow-up, the high-LDL group showed greater increases in serum total-cholesterol and LDL-cholesterol, plasma oxidized LDL, lipoprotein-associated phospholipase A2 activity, and urinary 8-epi-prostaglandin F2α than the control group after adjusting for baseline levels. The high-LDL group also showed significant decreases in sphingomyelin (SM) (d18:0/16:1) and phosphatidylcholine (PC) (18:0/20:4), which were associated with an increases on LDL-cholesterol, and significant increases in palmitic amide and lactosylceramide. Mean changes in the levels of SM (d18:0/16:1), C17 sphinganine, PC (18:0/20:4), and eight lysoPCs containing C16:1, C16:0, C17:0, C18:1, C18:0, C20:4, C20:3, and C22:6 were statistically different between control and high-LDL groups. Overall, the change in ox-LDL positively correlated with changes in LDL-cholesterol, Lp-PLA2 activity, palmitic amide, oleamide, lysoPCs, and C17 sphinganine, and negatively correlated with changes in SM (d18:0/16:1) (r = −0.501, P < 0.001). An age-related increase in LDL-cholesterol is associated with enhanced oxidative stress and disturbed sphingolipid metabolism.
AB - We investigated alterations in plasma metabolites associated with the age-related increase in circulating concentration of low-density lipoprotein (LDL)-cholesterol. The study included 602 healthy, nondiabetic subjects (aged 30–65 years). Among 393 individuals with LDL-cholesterol within the normal limit at baseline, 56 (14.2 %) developed high fasting LDL-cholesterol levels after 3 years. The 337 subjects that retained normal LDL-cholesterol were matched for age, gender, BMI, and fasting LDL-cholesterol to form the control group (n = 78). At the 3-year follow-up, the high-LDL group showed greater increases in serum total-cholesterol and LDL-cholesterol, plasma oxidized LDL, lipoprotein-associated phospholipase A2 activity, and urinary 8-epi-prostaglandin F2α than the control group after adjusting for baseline levels. The high-LDL group also showed significant decreases in sphingomyelin (SM) (d18:0/16:1) and phosphatidylcholine (PC) (18:0/20:4), which were associated with an increases on LDL-cholesterol, and significant increases in palmitic amide and lactosylceramide. Mean changes in the levels of SM (d18:0/16:1), C17 sphinganine, PC (18:0/20:4), and eight lysoPCs containing C16:1, C16:0, C17:0, C18:1, C18:0, C20:4, C20:3, and C22:6 were statistically different between control and high-LDL groups. Overall, the change in ox-LDL positively correlated with changes in LDL-cholesterol, Lp-PLA2 activity, palmitic amide, oleamide, lysoPCs, and C17 sphinganine, and negatively correlated with changes in SM (d18:0/16:1) (r = −0.501, P < 0.001). An age-related increase in LDL-cholesterol is associated with enhanced oxidative stress and disturbed sphingolipid metabolism.
UR - http://www.scopus.com/inward/record.url?scp=84927510807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927510807&partnerID=8YFLogxK
U2 - 10.1007/s11306-014-0669-3
DO - 10.1007/s11306-014-0669-3
M3 - Article
AN - SCOPUS:84927510807
VL - 11
SP - 40
EP - 49
JO - Metabolomics
JF - Metabolomics
SN - 1573-3882
IS - 1
ER -